Cynata Therapeutics Ltd has released a press release.
December 2019 Quarterly Report
Filed with ASX ·
6ix hasn’t read this filing yet.
Cynata Therapeutics Limited on 6ix
In the deck
Story so far
Earlier from Cynata Therapeutics
- Cynata Therapeutics: UK Regulatory Authority Approves Cynata’s Phase 2 Clinical Trial in Critical Limb Ischaemia
- Cynata Receives UK Regulatory Approval for CLI Trial
- Cynata Receives $1.892m R&D Tax Incentive Refund
- Cymerus MSCs Effective in Preclinical Model of Sepsis
- CYP Files Application to Commence Phase 2 CLI Clinical Trial
Later from Cynata Therapeutics
- Notice of Allowance from Israel Patent Office
- Market Update & Additional A$618k R&D Tax Refund
- Cynata provides guidance on planned clinical trials
- Cynata MSCs beneficial in preclinical ARDS study
- Cynata announces $5.55m capital raising
Follow Cynata Therapeutics into a list and get an email when it puts out news.
Follow Cynata Therapeutics